Evidence map›Paper›PMID 24990615›Full record

Trial reportLeukemia2014

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.

W E Pierceall, S L Warner, R J Lena, C Doykan, N Blake, M Elashoff, D V Hoff, D J Bearss, M H Cardone, L Andritsos and 4 more

2 registry-linked trialsAbstract readLetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00058240 phase1 / phase2completednot on this map

A Dose-Escalation Study of Flavopiridol (NSC 649890) Administered as a 30 Minute Loading Dose Followed by a 4-Hour Infusion in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2003 to 2009Enrolled52ConditionsB-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Waldenström MacroglobulinemiaArmsalvocidib
NCT00098371 phase2terminatednot on this map

A Phase II Study of Flavopiridol Administered as a 30 Minute Loading Dose Followed by a 4-Hour Continuous Infusion in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From CLL

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2005 to 2012Enrolled64ConditionsB-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic LeukemiaArmsalvocidib
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

W E PierceallEutropics Inc., Cambridge, MA, USA.
S L WarnerTolero Pharmaceuticals, Inc., Lehi, UT, USA.
R J LenaEutropics Inc., Cambridge, MA, USA.
C DoykanEutropics Inc., Cambridge, MA, USA.
N BlakeEutropics Inc., Cambridge, MA, USA.
M ElashoffEutropics Inc., Cambridge, MA, USA.
D V Hoff1] Tolero Pharmaceuticals, Inc., Lehi, UT, USA [2] Translational Genomics Research Institute, Scottsdale, AZ, USA.
D J BearssTolero Pharmaceuticals, Inc., Lehi, UT, USA.
M H CardoneEutropics Inc., Cambridge, MA, USA.
L AndritsosDepartment of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
J C ByrdDepartment of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
M C LanasaDepartment of Medicine, Duke Cancer Institute, Durham, NC, USA.
M R GreverDepartment of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
A J JohnsonDepartment of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

Funding

Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
UM1 Supplement for Early Therapeutic Trials with Phase 2 IntentUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON · 2014 to 2026
$19.3M
SPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI MARCUCCI, GUIDO · 2009 to 2013
$11.2M
NCI NIH HHS HHSN261201200039CNCI NIH HHS P01 CA081534NCI NIH HHS P50 CA140158NCI NIH HHS UM1 CA186712
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agentsbcl-X ProteinDrug Resistance, NeoplasmFemaleFlavonoidsHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedMitochondriaPiperidinesalvocidibAntineoplastic AgentsBCL2L1 protein, humanbcl-X ProteinFlavonoidsPiperidines

Identifiers

PMID24990615
PMCPMC4221486

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.